Arase Therapeutics

Arase Therapeutics is a private, pre-clinical stage biotech founded in 2021, targeting novel enzymes in oncology and immunology. The company's core platform centers on inhibiting ADP-ribose Hydrolases, which are involved in critical cancer stress response pathways, positioning it for first-in-class drug discovery. With minimal public data on pipeline specifics, leadership, or funding, the company appears to be in an early, stealth-like R&D phase. Its success will hinge on validating its novel target approach and advancing candidates into the clinic.

Platform focused on developing inhibitors of ADP-ribose Hydrolases, novel enzyme targets involved in cancer stress response pathways like DNA damage repair.

Operates in the competitive DNA Damage Response (DDR) inhibitor space, dominated by approved PARP inhibitors. Competition includes companies developing next-generation PARP inhibitors and therapies targeting other DDR nodes (e.g., ATR, ATM, CHK1 inhibitors). A few biotechs may be exploring similar hydrolase targets, but it remains a nascent field.